Literature DB >> 17056630

Prevalence of haemochromatosis gene mutations in Parkinson's disease.

Anne Hege Aamodt1, Lars Jacob Stovner, Ketil Thorstensen, Stian Lydersen, Linda R White, Jan O Aasly.   

Abstract

The aim of this study was to investigate a possible association between haemochromatosis (HFE) gene mutations and the prevalence of Parkinson's disease. The HFE gene encodes a protein that modulates iron absorption. Several studies have documented increased iron levels in the basal ganglia in patients with Parkinson's disease. In a study on patients with concurrent hereditary haemochromatosis and Parkinson's disease, abnormal deposition of iron in the basal ganglia was suggested as an inductor of Parkinson's disease. In this study, genotype frequencies of the HFE mutations C282Y, H63D and S65C were estimated in 388 patients with Parkinson's disease and compared with frequencies found in comparable studies. No significant differences were found in frequencies between the patients and comparable populations. This study does not indicate increased susceptibility to Parkinson's disease in HFE gene mutation carriers in Norway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056630      PMCID: PMC2117639          DOI: 10.1136/jnnp.2006.101352

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

Review 1.  Parkinson's disease. First of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

Review 2.  Iron metabolism and Parkinson's disease.

Authors:  E C Hirsch; B A Faucheux
Journal:  Mov Disord       Date:  1998       Impact factor: 10.338

Review 3.  Clinical report of three patients with hereditary hemochromatosis and movement disorders.

Authors:  G Demarquay; A Setiey; Y Morel; C Trepo; G Chazot; E Broussolle
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

4.  High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression.

Authors:  S Distante; J P Berg; K Lande; E Haug; H Bell
Journal:  Scand J Gastroenterol       Date:  1999-05       Impact factor: 2.423

5.  HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.

Authors:  C Mura; O Raguenes; C Férec
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  The basal ganglia in haemochromatosis.

Authors:  D Berg; U Hoggenmüller; E Hofmann; R Fischer; M Kraus; M Scheurlen; G Becker
Journal:  Neuroradiology       Date:  2000-01       Impact factor: 2.804

7.  Clinical features of LRRK2-associated Parkinson's disease in central Norway.

Authors:  Jan O Aasly; Mathias Toft; Ignacio Fernandez-Mata; Jennifer Kachergus; Mary Hulihan; Linda R White; Matthew Farrer
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

8.  Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.

Authors:  A Asberg; K Hveem; K Thorstensen; E Ellekjter; K Kannelønning; U Fjøsne; T B Halvorsen; H B Smethurst; E Sagen; K S Bjerve
Journal:  Scand J Gastroenterol       Date:  2001-10       Impact factor: 2.423

9.  The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients.

Authors:  D D Buchanan; P A Silburn; J B Chalk; D G Le Couteur; G D Mellick
Journal:  Neurosci Lett       Date:  2002-07-19       Impact factor: 3.046

Review 10.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01
View more
  13 in total

Review 1.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

2.  Association study between four polymorphisms in the HFE, TF and TFR genes and Parkinson's disease in southern Italy.

Authors:  Valentina Greco; Elvira Valeria De Marco; Francesca Emanuela Rocca; Ferdinanda Annesi; Donatella Civitelli; Giovanni Provenzano; Patrizia Tarantino; Vittorio Scornaienchi; Franco Pucci; Maria Salsone; Fabiana Novellino; Maurizio Morelli; Sandra Paglionico; Antonio Gambardella; Aldo Quattrone; Grazia Annesi
Journal:  Neurol Sci       Date:  2011-03-08       Impact factor: 3.307

Review 3.  Iron homeostasis in osteoporosis and its clinical implications.

Authors:  G F Li; Y Z Pan; P Sirois; K Li; Y J Xu
Journal:  Osteoporos Int       Date:  2012-04-14       Impact factor: 4.507

4.  Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

Authors:  R Savica; B R Grossardt; J M Carlin; M Icen; J H Bower; J E Ahlskog; D M Maraganore; D P Steensma; W A Rocca
Journal:  Neurology       Date:  2009-10-27       Impact factor: 9.910

Review 5.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

6.  Eryptosis as a marker of Parkinson's disease.

Authors:  Etheresia Pretorius; Albe C Swanepoel; Antoinette V Buys; Natasha Vermeulen; Wiebren Duim; Douglas B Kell
Journal:  Aging (Albany NY)       Date:  2014-10       Impact factor: 5.682

7.  Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease.

Authors:  Dominic J Hare; Bárbara Rita Cardoso; Erika P Raven; Kay L Double; David I Finkelstein; Ewa A Szymlek-Gay; Beverley-Ann Biggs
Journal:  NPJ Parkinsons Dis       Date:  2017-01-05

8.  Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study.

Authors:  Irene Pichler; Fabiola Del Greco M; Martin Gögele; Christina M Lill; Lars Bertram; Chuong B Do; Nicholas Eriksson; Tatiana Foroud; Richard H Myers; Michael Nalls; Margaux F Keller; Beben Benyamin; John B Whitfield; Peter P Pramstaller; Andrew A Hicks; John R Thompson; Cosetta Minelli
Journal:  PLoS Med       Date:  2013-06-04       Impact factor: 11.069

Review 9.  Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.

Authors:  Scott Ayton; Peng Lei
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

Review 10.  Parkinson's Disease: The Mitochondria-Iron Link.

Authors:  Yorka Muñoz; Carlos M Carrasco; Joaquín D Campos; Pabla Aguirre; Marco T Núñez
Journal:  Parkinsons Dis       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.